Eagle Pharmaceuticals (EGRX)
$60.00 0.86 (1.45%)
16:41 EST EGRX Stock Quote Delayed 15 Minutes
Previous Close $60.00
Market Cap 890.13M
PE Ratio 29.70
Volume (Avg. Vol.) 274,500
Day's Range 58.54 - 61.31
52-Week Range 36.03 - 64.94
Dividend & Yield N/A (N/A)
EGRX Stock Predictions, Articles, and Eagle Pharmaceuticals News
- From InvestorPlace
- From the Web
An Obamacare replacement is back in the news, and these seven A-rated healthcare stocks are winners regardless of how it shakes out.
The second quarter is about making money without worrying about Washington or Wall Street. These seven are the "best of the best" stocks to buy for Q2.
The world was shocked by Donald Trump's surprise victory, but few equities will benefit as much as big pharma stocks.
This week, 22 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Why Cypress Semiconductor Corporation (CY), Eagle Pharmaceuticals Inc (EGRX) and Energy Transfer Equity LP (ETE) Are 3 of Today’s Worst Stocks
Cypress Semiconductor (CY), Eagle Pharmaceuticals (EGRX) and Energy Transfer Equity (ETE) were left out of Monday's mostly market-wide rally.
The ratings of 27 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
If you're a fan of growth stocks and healthcare stocks ... well, these seven names would've done you well in 2015. A few of them could keep soaring.
From Seeking Alpha
NetworkNewsBreaks – Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Commences Dosing in Estrogen Receptor Pilot Study
Eagle Pharmaceuticals (NASDAQ: EGRX) on Monday announced that it has initiated dosing in a pilot clinical study to evaluate the unique characteristics of fulvestrant, EGRX’s product candidate that has the potential to enhance estrogen receptor (“ER”) inhibition and improve patient outcomes. The company will utilize the results of the pilot study to advise the design […]
From Seeking Alpha
From Market News Video
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ciena Corp (CIEN), where a total volume of 10,788 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 56.1% of CIEN's average daily trading volume over the past month, of 1.9 million shares..
From Simply Wall St
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We’ll show how you can use Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) P/E<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-egrx/eagle-pharmaceuticals/news/why-eagle-pharmaceuticals-inc-s-nasdaqegrx-high-p-e-ratio-isnt-necessarily-a-bad-thing/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader